• BioNTech’s CEO, Ugur Sahin, suggests that a new formulation of the coronavirus vaccine it co-developed with Pfizer is likely to be needed for new variants by mid-2022. “This virus will stay, and the virus will further adapt,” he said, adding, “We have no reason to assume that the next generation virus will be easier to handle for the immune system than the existing generation. This is a continuous evolution, and that evolution has just started.” Source
• The European Medicines Agency recommended a booster dose of the Pfizer /BioNTech coronavirus vaccine at least six months after the second dose for people over age 18 years, based on data from Pfizer that show increased antibody levels after a booster. EMA also recommendedan mRNA booster for immunocompromised people at least 28 days after the second dose. Source